false
0001795091
0001795091
2026-03-31
2026-03-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 31, 2026
OS THERAPIES INCORPORATED
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-42195 |
|
82-5118368 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
115 Pullman Crossing Road, Suite 103
Grasonville, Maryland |
|
21638 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (410) 297-7793
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| |
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which Registered |
| Common Stock, par value $0.001 per share |
|
OSTX |
|
NYSE American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
CURRENT
REPORT ON FORM 8-K
OS
Therapies Incorporated
March
31, 2026
Item
1.01. Entry into a Material Definitive Agreement.
Securities
Purchase Agreement
On March 31, 2026, OS Therapies
Incorporated (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the
purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company offered for sale to
the Purchasers in a registered direct offering (the “Offering”) an aggregate of 2,505,073 shares of its common stock and,
in lieu thereof, pre-funded warrants to purchase up to 1,250,893 shares of its common stock (the “pre-funded warrants”), and
accompanying warrants to purchase up to 3,755,966 shares of its common stock (the “common warrants”). The shares of common
stock, pre-funded warrants and common warrants (including the shares of common stock underlying the pre-funded warrants and common warrants)
were offered by the Company pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-289443) filed by the
Company with the U.S. Securities and Exchange Commission (the “Commission”) on August 8, 2025 and declared effective by the
Commission on August 12, 2025 (the “Registration Statement”), and the prospectus supplement dated March 31, 2026 filed by
the Company with the Commission on April 2, 2026 (the “Prospectus Supplement”).
The combined purchase price
for each share and common warrant in the Offering was $1.40, and the purchase price for each pre-funded warrant and common warrant in
the Offering was $1.399, which is equal to the per share and common warrant purchase price, minus $0.001. The closing of the Offering
occurred on April 2, 2026. The Company received net proceeds from the Offering of approximately $4.7 million. The Company intends
to use the net proceeds to fund clinical development activities, including ongoing and planned clinical trials, advance its research and
development programs, and acquire or invest in technologies, product candidates or businesses that are complementary to its strategic
objectives, as well as for working capital and other general corporate purposes.
The Purchase Agreement contains
customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including
for liabilities arising under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.
Pursuant to the Purchase Agreement,
the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common
stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement
or prospectus, or any amendment or supplement thereto, for 90 days after the closing date of the Offering, subject to certain exceptions.
The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible
into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement)
until 180 days after the closing date of the Offering.
Placement
Agent Agreement
In
connection with the Offering, on March 31, 2026, the Company entered into a placement agency agreement (the “Placement Agent Agreement”)
with Ceros Financial Services, Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s
exclusive placement agent in connection with the Offering. The Company agreed to pay the Placement Agent a cash fee equal to 7.0% of
the gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent up to $70,000 for its reasonable
and documented out-of-pocket accountable expenses and up to $20,000 for its non-accountable expenses.
The Company also issued to
the Placement Agent, or its designees, warrants (the “placement agent warrants”) to purchase up to 187,798 shares of the Company’s
common stock (equal to 5.0% of the aggregate number of shares of common stock and pre-funded warrants sold in the Offering). The placement
agent warrants have an exercise price of $1.54 per share (which represents 110% of the offering price per share and accompanying common
warrant), are exercisable beginning six months after the date of issuance and expire five years from April 2, 2026.
In
addition to the shares of common stock, the pre-funded warrants and the common warrants (including the shares of common stock underlying
the pre-funded warrants and common warrants), the placement agent warrants and the shares of common stock underlying the placement agent
warrants were offered by the Company pursuant to the Registration Statement and the Prospectus Supplement.
The
Placement Agent Agreement contains customary representations, warranties, and agreements by the Company, indemnification obligations
of the Company, other obligations of the parties and termination provisions.
Terms
of the Pre-Funded Warrants
The
following summary of certain terms and provisions of the pre-funded warrants is not complete and is subject to, and qualified in its
entirety by, the provisions of the pre-funded warrants, the form of which is filed as Exhibit 4.1 to this Current Report on Form 8-K
and incorporated herein by reference.
Duration and Exercise
Price. Each pre-funded warrant is exercisable at any time beginning on the date of issuance and expires only when fully exercised.
Each pre-funded warrant entitles the holder thereof to purchase shares of the Company’s common stock at an exercise price equal
to $0.001 per share. The exercise price and number of shares of the Company’s common stock issuable upon exercise of each pre-funded
warrant is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company’s
common stock and the exercise price.
Exercisability.
The holder of the pre-funded warrant may exercise the pre-funded warrant by delivering an exercise notice, completed and duly signed,
and payment in cash of the exercise price for the number of shares of the Company’s common stock for which the pre-funded warrant
is being exercised. The holder of the pre-funded warrant may also satisfy its obligation to pay the exercise price through a “cashless
exercise,” in which the holder receives the net value of the pre-funded warrant in shares of common stock determined according
to the formula set forth in the pre-funded warrant.
A
holder of the pre-funded warrant will not be entitled to exercise any portion of such pre-funded warrant that, upon giving effect to
such exercise, would cause the aggregate number of shares of the Company’s common stock beneficially owned by such holder (together
with its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder for purposes
of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) to exceed 4.99% (or, at the
holder’s election, 9.99%) of the total number of then issued and outstanding shares of the Company’s common stock, as such percentage
ownership is determined in accordance with the terms of the pre-funded warrant and subject to such holder’s rights under the pre-funded
warrant to increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days’
prior notice from such holder to the Company.
Fundamental
Transaction. In the event of any fundamental transaction, as described in the pre-funded warrants and generally including any
merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or
reclassification of the Company’s shares of common stock, then upon any subsequent exercise of a pre-funded warrant, the holder
will have the right to receive as alternative consideration, for each share of common stock that would have been issuable upon such exercise
immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring
corporation of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such
transaction by a holder of the number of shares of common stock for which the warrant is exercisable immediately prior to such event.
Transferability.
Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant
to the Company together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable).
Exchange
Listing. There is no established public trading market available for the pre-funded warrants on any securities exchange or nationally
recognized trading system. The Company does not intend to list the pre-funded warrants on the NYSE American or any other securities exchange
or nationally recognized trading system.
The
Company will initially serve as the warrant agent for the pre-funded warrants.
Right
as a Stockholder. Except as otherwise provided in the pre-funded warrants or by virtue of such holder’s ownership
of shares of the Company’s common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders
of the Company’s common stock, including any voting rights, until they exercise their pre-funded warrants.
Terms
of the Common Warrants
The
following summary of certain terms and provisions of the common warrants is not complete and is subject to, and qualified in its entirety
by, the provisions of the common warrants, the form of which is filed as Exhibit 4.2 to this Current Report on Form 8-K and incorporated
herein by reference.
Duration and Exercise
Price. Each common warrant is immediately exercisable upon issuance and expires five years from the date of issuance. Each common
warrant entitles the holder thereof to purchase shares of the Company’s common stock at an exercise price equal to $1.40 per share.
The exercise price and number of shares of the Company’s common stock issuable upon exercise of each common warrant is subject to
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company’s common stock
and the exercise price.
Exercisability.
The holder of the common warrant may exercise the common warrant by delivering an exercise notice, completed and duly signed,
and payment in cash of the exercise price for the number of shares of the Company’s common stock for which the common warrant is
being exercised. The holder of the common warrant may also satisfy its obligation to pay the exercise price through a “cashless
exercise,” in which the holder receives the net value of the common warrant in shares of common stock determined according to the
formula set forth in the common warrant.
A
holder of the common warrant will not be entitled to exercise any portion of such common warrant that, upon giving effect to such exercise,
would cause the aggregate number of shares of the Company’s common stock beneficially owned by such holder (together with its affiliates
and any other persons whose beneficial ownership of common stock would be aggregated with the holder for purposes of Section 13(d) of
the Exchange Act) to exceed 4.99% (or, at the holder’s election, 9.99%) of the total number of then issued and outstanding shares
of the Company’s common stock, as such percentage ownership is determined in accordance with the terms of the common warrant and
subject to such holder’s rights under the common warrant to increase or decrease such percentage to any other percentage not in
excess of 19.99% upon at least 61 days’ prior notice from such holder to the Company.
Fundamental
Transactions. In the event of any fundamental transaction, as described in the common warrants and generally including any merger
with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or reclassification
of the Company’s shares of common stock, then upon any subsequent exercise of a common warrant, the holder will have the right
to receive as alternative consideration, for each share of common stock that would have been issuable upon such exercise immediately
prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation
of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction
by a holder of the number of shares of common stock for which the warrant is exercisable immediately prior to such event.
Transferability.
Subject to applicable laws, a common warrant may be transferred at the option of the holder upon surrender of the common warrant
to the Company together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable).
Exchange
Listing. There is no established public trading market available for the common warrants on any securities exchange or nationally
recognized trading system. The Company does not intend to list the common warrants on the NYSE American or any other securities exchange
or nationally recognized trading system.
The
Company will initially serve as the warrant agent for the common warrants.
Right
as a Stockholder. Except as otherwise provided in the common warrants or by virtue of such holder’s ownership of shares
of the Company’s common stock, the holders of the common warrants do not have the rights or privileges of holders of the Company’s
common stock, including any voting rights, until they exercise their common warrants.
The
foregoing descriptions of the Placement Agent Agreement, the pre-funded warrants, the common warrants, the placement agent warrants and
the Purchase Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Placement
Agent Agreement and the forms of pre-funded warrant, common warrant, placement agent warrant and Purchase Agreement, copies of which
are filed as Exhibits 1.1, 4.1, 4.2, 4.3 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
The
representations, warranties and covenants contained in the Purchase Agreement and the Placement Agent Agreement were made only for purposes
of each such agreement and as of specific dates, were solely for the benefit of the parties thereto and may be subject to limitations
agreed upon by the contracting parties. Accordingly, the Purchase Agreement and the Placement Agent Agreement are incorporated herein
by reference only to provide investors with information regarding the terms of the Purchase Agreement and the Placement Agent Agreement
and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction
with the disclosures in the Company’s periodic reports and other filings with the Commission.
The
legal opinion, including the related consent, of Olshan Frome Wolosky LLP relating to the issuance and sale of the Company’s securities
in the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.
This
Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or jurisdiction.
Item 8.01. Other Events.
On April 2, 2026, the Company issued a press release announcing the
closing of the Offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Forward-Looking
Statements
This Current Report on Form
8-K, including Exhibit 99.1 hereto, contains forward-looking statements that involve risks and uncertainties, such as statements related
to the intended use of the net proceeds from the Offering. The risks and uncertainties involved include the Company’s financial
position, market conditions and other risks detailed from time to time in the Company’s periodic reports and other filings with
the Commission. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current
expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to revise or
update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise, except
as required by U.S. federal securities law.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number |
|
Description
|
| 1.1 |
|
Placement Agency Agreement, dated as of March 31, 2026, by and between OS Therapies Incorporated and Ceros Financial Services, Inc. |
| 4.1 |
|
Form of Pre-Funded Warrant. |
| 4.2 |
|
Form of Common Warrant. |
| 4.3 |
|
Form of Placement Agent Warrant. |
| 5.1 |
|
Opinion of Olshan Frome Wolosky LLP. |
| 10.1* |
|
Form of Securities Purchase Agreement. |
| 23.1 |
|
Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1). |
| 99.1 |
|
Press Release issued by OS Therapies Incorporated on April 2, 2026. |
| 104 |
|
Cover Page Interactive Data File (embedded within the
Inline XBRL document). |
| * | Pursuant
to Item 601(a)(5) of Regulation S-K, certain schedules and exhibits have been
omitted. The registrant agrees to furnish supplementally a copy of any omitted schedule or
exhibit to the Commission upon its request. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
OS THERAPIES INCORPORATED |
| |
|
| Dated: April 2, 2026 |
By: |
/s/
Paul A. Romness, MPH |
| |
|
Name: |
Paul A. Romness, MPH |
| |
|
Title: |
President and Chief Executive Officer |
Exhibit 99.1
OS Therapies Completes
$5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
| ● | Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26 |
| ● | Company expects to receive approximately $2 million in non-dilutive R&D tax credits repayable to the company in cash from its
U.K. subsidiary in 2H-26 |
| ● | Offering net proceeds, together with funds expected to be received via U.K. subsidiary, expected to provide cash runway into 2027 |
| ● | Company expects to receive approvals in the U.S., U.K. and Europe for OST-HER2 in the prevention of delay of recurrent, fully resected,
pulmonary metastatic osteosarcoma in the second half of 2026 |
New York, NY,
April 2, 2026 – OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), the world
leader in gene-edited, listeria-based cancer immunotherapies, today announced it that it has completed a $5.25 million registered
direct offering of common stock (or pre-funded warrants in lieu thereof) and warrants, with participation primarily from
high-net-worth investors who have invested in several of the Company’s prior financing rounds. Each investor was issued either
shares of common stock at a purchase price of $1.40 per share or, in lieu thereof, pre-funded warrants at a purchase price of $1.399
per pre-funded warrant, together with one warrant to purchase one share of common stock at an exercise price of $1.40 per share for
each share of common stock issued or issuable upon exercise of the pre-funded warrants. Additional details related to the offering
are included in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the
“SEC”) on April 2, 2026. Ceros Financial Services, Inc. acted as the exclusive placement agent for the offering.
Additionally, the Company announced that it
expects to receive approximately $4 million in additional non-dilutive funds from VAT refunds and R&D reclaim funds via its wholly
owned U.K. subsidiary that was established in 2025 for the purpose of conducting research & development.
“This capital raise, together with the
non-dilutive funding we expect to receive from our U.K. subsidiary, is expected to support our operations as we advance toward crucial
anticipated 2026 regulatory milestones for OST-HER2 in the U.S., U.K. and Europe, including early market access authorizations and potential
eligibility for a Priority Review Voucher (PRV) under our Rare Pediatric Disease Designation (RPDD),” said Paul Romness, President
& CEO of OS Therapies. “We are now focused on our upcoming regulatory interactions, including planned meetings later this quarter
with the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), the U.K. Medicines and Healthcare products Regulatory
Agency (MHRA) and the Australian Therapeutic Goods Administration (TGA) to review our clinical and biomarker data, as well as our proposed
confirmatory Phase 3 trial design. We are hopeful these interactions will support market access for osteosarcoma patients beginning in
2027. This funding is also expected to support the initiation of a Phase 3 confirmatory trial, including the planned activation of an
initial trial site in Australia, which is part of the requirements for a Biologics License Application (BLA) under the U.S. Accelerated
Approval Program (Accelerated Approval) and for Conditional Marketing Authorisations (CMAs) in the U.K. and Europe.”
OST-HER2 has received Orphan Drug Designation
(ODD), Fast Track Designation (FTD) and RPDD from the FDA, and ODD, FTD and ATMP from the EMA. Under the RPDD program, if the Company
receives a BLA in the United States, it will become eligible to receive a PRV that it intends to sell, subject to market conditions. The
most recent publicly disclosed PRV transaction occurred in February 2026 at a reported value of $205 million; however, there can be no
assurance that the Company would realize a comparable value, if any, in connection with any future PRV sale. The Company is seeking to
obtain a BLA under the Accelerated Approval Program for OST-HER2 in osteosarcoma in the second half of 2026.
The securities described above were offered
pursuant to a “shelf” registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August
8, 2025 and declared effective by the SEC on August 25, 2025. The offering was made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating
to the securities being offered were filed with the SEC and are available at the SEC’s website at www.sec.gov. Electronic copies
of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting
Ceros Financial Services, Inc. at 1445 Research Boulevard, Rockville, Maryland 20850, or e-mail Ahmed Gheith, Managing Director at Ceros
at agheith@cerosfs.com.
No Offer to Sell or Solicit
This press release is for informational purposes
only and does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall
there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or jurisdiction.
About OS Therapies
OS Therapies is a clinical stage oncology
company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.
The Company is the world leader in listeria-based cancer immunotherapies. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging
the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received
Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug
Administration and has received ODD, FTD and ATMP from the European Medicines Agency. The Company reported positive data in its Phase
2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit
in the 12-month event free survival (EFS) primary endpoint of the study and the overall survival (OS) secondary endpoint. The Company
anticipates receiving a Biologics License Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026 and, if approved, would
become eligible to receive a Priority Review Voucher that it could then sell. The Company also anticipates receiving Conditional Marketing
Authorisations from the U.K.’s Medicines and Healthcare products Regulatory Agency and the EMA for OST-HER2 in 2026. OST-HER2 has
completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models
of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
The Company also anticipates reading out data from a Phase 1b study of OST-504 in castration resistant prostate cancer in the first half
of 2026.
In addition, OS Therapies is advancing its
next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored
antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone Si-Linker and Conditionally Active Payload
(CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking
statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,”
“expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks
and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements
regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which
such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations
and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results
to differ materially, including, but not limited to our expected to provide cash runway into 2027, the intended use of net proceeds from
the offering, the potential approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in “Risk Factors”
in the Company’s most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and
Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required
by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
media@ostherapies.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
